4-(7azaoxindol-3-yl)-7-(3-morpholinopropoxy)quinazoline | 220895-28-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 4-(7azaoxindol-3-yl)-7-(3-morpholinopropoxy)quinazoline
• 英文别名: 3-[7-(3-Morpholin-4-ylpropoxy)quinazolin-4-yl]-1,3-dihydropyrrolo[2,3-b]pyridin-2-one
• CAS: 220895-28-3
• 化学式: C₂₂H₂₃N₅O₃
• 分子量: 405.456
• InChiKey: QRFCPDDYXQTSPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  89.5
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS
  申请人：ZENECA LIMITED

  公开号：EP1005470A1

  公开（公告）日：2000-06-07
• NEW USE
  申请人：AstraZeneca AB

  公开号：EP1458395A1

  公开（公告）日：2004-09-22
• MEDICAL USE OF GSK3-INHIBITING OXINDOLE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1458395B1

  公开（公告）日：2007-11-28
• Use
  申请人：Berg Stefan

  公开号：US20050075351A1

  公开（公告）日：2005-04-07

  The present invention relates to a new use of oxindole derivatives of formula I, as a free base or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the prevention and/or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3. Formula (I) wherein R 1 , R 2 , R 3 , ring Z, m and n are as defined as in claim 1 . The present invention further relates to a method of prevention and/or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3, as well as a pharmaceutical composition for said use.
• US6294532B1
  申请人：——

  公开号：US6294532B1

  公开（公告）日：2001-09-25